BLRX (BioLine Rx) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLRX BioLine Rx Ltd BLRX
25 GF Score
Price $2.91
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

BLRX
25GF Score
BioLine Rx Ltd BLRX
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Business Description

Other Exchanges BLRX:IsraelYP2:Germany
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
25GF Score

Get the complete analysis for BLRX

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.91
Price